Background: Large clinical trials testing hydrocortisone therapy in septic shock have produced conflicting results. Subgroups may however benefit depending on their individual immune response.
Introduction
Though prospective, randomized, controlled multicentre trials have consistently reported faster shock resolution (1, 2) , the utility of 'low-dose' hydrocortisone (HC) in patients with septic shock remains controversial. Whereas two French studies reported outcome benefit from a combination of hydrocortisone plus oral fludrocortisone (3, 4) , the pan-European CORTICUS trial and the 5-country ADRENAL trial found no survival effect from hydrocortisone alone (2, 5) . Possible explanations for this disparity included differences in mortality risk in the populations with a two-fold higher risk of mortality in the French control group (of (1)) compared to CORTICUS (61% versus 31%, respectively), and an increase in superinfections, variations in other aspects of clinical management, and genetic variations.
Of note, a subset analysis of the ADRENAL trial indicated survival benefit from hydrocortisone in Australasian patients, no effect in British and Danish patients, and a trend to harm in patients enrolled in Saudi Arabia (2) .
It is increasingly recognized that patients presenting in septic shock are hyper-inflamed yet at the same time immunosuppressed (6) (7) (8) . Corticosteroids are traditionally considered to induce immune suppression via the glucocorticoid receptor (GR) and its repressive effect on pro-inflammatory transcription factors such as AP-1 and NFкB (9) . Thus, patients in an overall state of immunosuppression may be potentially compromised by administration of an immunosuppressive drug. This argument is however complicated by an increasing evidence base implicating corticosteroids and GRs in immune-reconstitutive processes (10, 11) . In human monocytes, corticosteroid treatment induced expression of innate immune-related genes, such as TLRs, and anti-inflammatory genes (10, 11) . In macrophages and derived cell lines glucocorticoids induced a central component of the inflammasome (NLRP3) and, upon stimulation with endotoxin, induced secretion of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFα) (11) . Furthermore, glucocorticoid-dependent NLRP3 induction resulted in sensitization of innate immune cells to extracellular ATP and thus an enhanced ATP-mediated secretion of pro-inflammatory cytokines following endotoxin stimulation (12) . This immune-activating role of corticosteroids has been described as a response to acute stress enhancing the peripheral immune response, whereas chronic corticosteroid exposure leads to immune suppression (13, 14) . These diverging effects of GCs support the need for biomarkers to guide their application. We applied machine learning to physiological and laboratory data from patients enrolled into a CORTICUS sub-study to determine a theranostic marker for hydrocortisone treatment. We found the ratio of serum interferon-γ (IFNγ) to interleukin-10 (IL-10) to identify specific sub-cohorts with increased and decreased survival upon treatment. We thus explored this predictive utility of this biomarker in further datasets of septic shock patients and performed in vitro mechanistic studies to explore the possible significance of this ratio.
Materials and Methods

The CORTICUS cohort
In addition to the standard CORTICUS protocol, the Berlin study group sampled blood for subsequent measurement of cytokines and other circulating inflammatory mediators from 84 patients in 13 participating sites. The study was approved by the local Ethics Committee (no: 153/2001). Written informed consent was obtained from patients, proxies or their legal representatives. Eligible patients were enrolled if they met the following inclusion criteria: clinical evidence of infection, evidence of a systemic response to infection, the onset of shock within the previous 72 hours and hypoperfusion or organ dysfunction attributable to sepsis. Notable exclusion criteria included an underlying disease process with a poor prognosis, life expectancy <24 hours, long-term immunosuppression, and treatment with long-term corticosteroids within the past 6 months or short-term corticosteroids within the past 4 weeks. Detailed eligibility criteria are given in Supplementary Table S1 and the original study (5) . Patients were randomized to receive either placebo or 200 mg hydrocortisone (HC)/day for 5 days, followed by a tapering dose until day 11. Demographic and baseline characteristics were extracted from the CORTICUS database. 79 out of 83 6 (95%) patients received norepinephrine at baseline while none received epinephrine. Blood samples were taken directly before an ACTH stimulation test and administration of the study medication. Table S2 shows the timing of blood sampling relative to the onset of shock.
Blood samples were collected on day 0, on day 2, on the morning of day 5 (end of full dose HC application), on day 12 (day after HC cessation), day 17 and 27. The soluble mediators interleukin-(IL)-6, -8, -10, -12 p70, IFNγ, TNFα, soluble TNF-receptor-I (sTNF-RI), soluble FAS (all OptEIA (™) Set Human, BD Biosciences, New Jersey, USA), and E-selectin (R&D, Minnesota, USA) were measured in serum, plasma, or culture supernatant by enzyme-linked immunosorbent assay (ELISA) according to the manufacturers' instructions. This included calculating calibration and standard curves. All measurements were performed in duplicate.
The cytokine and all other laboratory values were taken from the original study.
One patient was removed due to lack of cytokine data. For ten patients either IFNγ or IL10 were below the detection limit. Excluding these patients did not change the overall results (Supplementary Text S8). Of the remaining 83 patients, serum lactate values (pre-treatment) and temporal values were available in 53 and 41 patients, respectively. For full details, see Supplementary Text S1 and S2.
The Hellenic Sepsis Study Group (HSSG) cohort and two further cohorts for validation
Validation was performed on data obtained by the Hellenic Sepsis Study Group from septic shock patients with community-acquired pneumonia or intraabdominal infection. This study included a prospective collection of clinical data and biosamples from patients admitted to 45 study sites in Greece. Patients were enrolled after written informed consent provided by themselves or their legal representatives. Detailed eligibility criteria are given in Supplementary Table S1 . All enrolled patients had been reclassified into infection and sepsis using the Sepsis-3 classification criteria (15, 16) . In HC-treated patients 200 mg/day HC had been administered for 7 days followed by gradual tapering. Secreted cytokines were measured using the LEGENDplex Human Inflammation Panel (13-plex) (BioLegend, San Diego, USA) according to the manufacturer´s instructions with half of the reagents volume and sample incubation at 4°C overnight. After quality control and discarding data from patients dying or being discharged on the day of admission, a total of 162 eligible shock patients (HC treatment: n=63, No HC treatment: n=99) were selected. If only one of the cytokines (IFNγ or IL10) was below the detection limit, the respective value was set as the detection limit. Excluding these samples from the analysis did not alter the findings (Supplementary Text S8). For further details, see Supplementary Text S3 and Table S3 for patient characteristics. Furthermore, we investigated serum IFNγ/IL10 of patients in the placebo arm of the randomized placebo-controlled, trial of Sodium Selenite and Procalcitonin-guided antimicrobial therapy in Severe Sepsis (SISPCT) (17) . After propensity score matching, n=24 patients were included in the analysis (details about the study and statistics, see Supplementary Text S6). In addition, we analyzed serum IFNγ/IL10 of patients from an earlier small crossover study (18) (details about this study and the crossover scheme is given in Supplementary Text S7). In this study, the early arm got a comparable HC application as the HC arm of CORTICUS, and hence was also used for validating our marker. The cytokine values of the crossover study were taken from the original publication.
Ex vivo whole blood culture experiments
To assess biological plausibility of the data-driven biomarker IFNγ/IL10, we performed ex vivo whole blood culture experiments in which blood of healthy donors was spiked with a broad range of bacterial products to simulate pathogen load. 200 µL of diluted (HBSS (1:1, V/V) heparinized whole blood obtained from healthy volunteers (n=5, male, 20-25 years) was stimulated with serial dilutions either of LPS (endotoxin of E. coli B4:O111) (Sigma Aldrich) or lysates from two E. coli isolates obtained from septic patients). E. coli lysates were created by sonification, following heat inactivation, and a serial dilution of the obtained fragment stock was performed. Following incubation (37°C, 18 hours, gentle agitation at 2 rpm) plasma supernatant was prepared by centrifugation (2500g at room temperature for 10 min), secreted cytokine levels were measured using the LEGENDplex Human Inflammation Panel (13-plex) (BioLegend), as described above. Comparison was made to vehicle controls.
The rationale of the data analysis
We used the database consisting of 137 patient features (potential predictors) and 83 patients from the subcohort of the CORTICUS study population to perform an exploratory data analysis. This table also included the ratios of all cytokine combinations. We aimed to find a theranostic marker distinguishing HC responders (i.e. survivors) from non-responders (non-survivors). The complete list of available features is shown in Supplementary Table S4 and the workflow depicted in Supplementary Figure S1 .
We sought the best predictor of 28-day survival for the placebo arm using one-level decision trees (stumps) calculated by a leave-one-out cross-validation scheme. The best decision trees were chosen by intelligent enumeration. Table S5 lists the results from all 41 crossvalidation runs. Of these, the predictor and threshold, which was in most trees (i.e. the predictor IFNγ/IL10) was applied to the HC arm. In 39 out of 41 runs, the cutoff value was 0.95 and applied to the HC arm leading to the 39.8 percentile of all 83 samples. Patients whose IFNγ/IL10 ratio ranked among the first 39.8% patients were denoted "low-ratio patients", the others "high-ratio patients". When we weighted all non-surviving patients higher or lower, we observed a linear relation between the optimal percentile and the corresponding mortality rates. Hence, we calculated these optimal cutoffs to gain a calibration curve with which we determined the cutoff for the validation sets (see also Results and Discussion, details for the method are in Supplementary Text S2, Figure S2 ). All analyses were carried out in R (www.r-project.org) using custom scripts. Odds ratio and statistical significance calculations are described in Supplementary Text S2.
Ex vivo whole blood culture experiments
To assess biological plausibility of the data-driven biomarker IFNγ/IL10, we performed ex vivo whole blood culture experiments in which blood of healthy donors was spiked with a broad range of bacterial products to simulate pathogen load. 200 µL of diluted (HBSS (1:1, V/V) heparinized whole blood obtained from healthy volunteers (n=5, male, 20-25 years) was stimulated with serial dilutions either of LPS (bacterial endotoxin of E. coli B4:O111) (Sigma Aldrich) or lysates from two E. coli isolates obtained from septic patients). E. coli lysates were created by sonification, following heat inactivation, and a serial dilution of the obtained fragments stock was performed. Following exposition (37°C, 18 hours, gently agitation 2rpm) plasma supernatant was prepared by centrifugation (2.500g, RT, 10 min), secreted cytokine levels were measured using the LEGENDplex Human Inflammation Panel (13-plex) (BioLegend) as described above compared to vehicle control.
Results
Patient characteristics
Patient characteristics are summarized in Table 1 . Median plasma concentrations of soluble mediators and leukocytes were not significantly different between the arms at baseline ( Supplementary Table S6 ). Age differed but was not a confounder (see Supplementary Text S4). Supplementary Table S4 ). We performed a leave-one-out cross-validation with one-level decision trees (using only one predictor at a time) to the placebo arm to discriminate between 28-day-survivors and non-survivors. This led to a high true positive rate (83% , Table 2a ). In 95% of the cross-validation runs, the serum IFNγ/IL10 ratio (referred to as IFNγ/IL10 in the following) with the same threshold (39.8 percentile of IFNγ/IL10 from all patients) was selected by the algorithm as the best predictor. Patients which IFNγ/IL10 ratios ranked among the first 39.8% patients were denoted "low-ratio patients", the others "high-ratio patients". Upon applying this predictor to HC-treated patients, the reverse behaviour was observed with a high true negative rate i.e. a low IFNγ/IL10 indicated a high likelihood of survival (85%) ( Table 2b ). A significant interaction effect (p=0.0083) was observed between the IFNγ/IL10 ratio and the treatment (Supplementary Text S11, Figure S3 ). These observations were then compiled into a decision rule: no HC treatment if the ratio was high, and HC treatment if low. This decision rule yielded an odds ratio (OR) of survival of 3.03 [95% Cl: 1.05-8.75], p=0.031. Of note, neither IFNγ nor IL10 alone could allow this prediction. Our new treatment rule was applied to a validation dataset from the Hellenic Sepsis Study Group and to two smaller datasets from two other clinical trials. Table S3 summarizes demographics of the validation cohort. Applying IFNγ/IL10 to the group of HSSG patients, we observed a similar pattern as for the CORTICUS subgroup. High IFNγ/IL10 indicated distinct higher survival of the HC non-treated patients (50% versus 19%).
IFNγ/IL10 stratifies CORTICUS patients
Validation based on patients from the Hellenic Sepsis Study Group (HSSG) and two further datasets
In contrast, in the HC treated group we observed the opposite behaviour (28% versus 35%), yielding an odds ratio of OR=2.01 [95% CI: 1.04-3.88], P=0.026. As the survival rate of the HSSG patients was lower compared to CORTICUS, we had to adjust the threshold according to a calibration scheme based on the CORTICUS data explained in Methods. Figure 1 illustrates the potential of the theranostic marker to predict responders in both cohorts.
Adjusting for an imbalance in co-morbidities between HC treated and non-treated patients by propensity score matching led to the same result (Supplementary Text S3). Furthermore, we investigated serum IFNγ/IL10 of patients in 24 (propensity score matched) patients from the placebo arm of the randomized placebo-controlled, trial of Sodium Selenite and Procalcitonin-guided antimicrobial therapy in Severe Sepsis (SISPCT) (17) (details about the study and statistics, see Supplementary Text S6). All patients survived (n=3) if treated according to the rule, compared to 77% if not treated according to the rule. In addition, we analyzed serum IFNγ/IL10 of patients from an earlier small crossover study (18) in which the early arm got a comparable HC application as the HC arm of CORTICUS, and hence was also used for validating our marker (details about this study and the crossover scheme is given in Supplementary Text S7). In line to the results from CORTICUS, HSSG and SISPCT, low IFNγ/IL10 indicated good survival (88% survivors), whereas high IFN/IL10 was an indicator for considerably worse outcome (57% survivors), for HC treatment the survival rates between IFNγ/IL10 high and low were comparable (Table 2e ). Due to the small sample sizes the results from SISPCT and the crossover study failed to achieve significance. In summary, the investigated patients from all studies evidenced IFNγ/IL10 as a potential theranostic marker for HC application in septic shock.
Time courses of serum lactate and norepinephrine requirement reflect hemodynamic stabilization in patients treated in compliance with the decision rule
High serum lactate levels have been demonstrated to indicate severity of metabolic derangements and increased mortality in sepsis (15) . Median initial lactate was 1.89 mmol/L in patients with high compared to 2.89 mmol/L in patients with low IFNγ/IL10 suggesting that IFNγ/IL10 associated with disease severity (boxplots, see Supplementary Figure S4 ). Of note, although the lactate levels correlate inversely with IFNγ/IL10 at baseline, serum lactate itself performed worse as a theranostic marker. Notably, we identified significant lactate decrease specifically in the group of patients, which were treated in compliance with the decision rule (Figure 2 a-d ). Hemodynamic stabilization was also supported by the reduction of norepinephrine (NE) requirement (P = 2.0e-05) specifically in the group of patients in compliance with the decision rule ( Figure 2 e-h). In summary, time series of serum lactate and NE requirement reflect better recovery of septic shock in patients treated in compliance with the proposed theranostic marker.
IFNγ/IL10 as an indicator of pathogen load
In light of published evidence associating IFNγ and IL10 with the severity of parasitic and tuberculosis infection, we investigated whether IFNγ/IL10 reflects the pathogen burden of immune cells when challenged with typical pathogens found in sepsis. We spiked blood from healthy donors with E. coli fragments from clinical isolates or endotoxin across a wide range of concentrations, mimicking the immunological load. As expected, the higher the load, the higher the immune response and hence the concentration of IFNγ and IL10 in the supernatant (Figure 3a, b) . Remarkably, we observed the inverse behaviour for the ratio, i.e. a high IFNγ/IL10 was observed for low pathogen concentrations and vice versa with "on-off" kinetics ( Figure 3c ). Results for a second E. coli isolate or endotoxin were similar (Supplementary Figure S5) . To associate IFNγ/IL10 to the bacterial load in critical ill patients, we compared publically available data of patients with and without bacteremia. Matera et al. 
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The corticotropin test and IFNγ/IL10 correlation to the severity of septic shock
Poor response to corticotropin stimulation is no longer recommended for HC treatment (3).
We tried several machine learning concepts to stratify for treatment using serum HC baseline and after corticotropin stimulation. In line to results of the original study (5) , the corticotropin test failed to predict response to treatment (Figure 1b , Supplementary Text S10, Table S7 ).
We further investigated if IFNγ/IL10 correlates with the severity of septic shock. However, IFNγ/IL10 did neither correlate with mean arterial pressure nor with the SOFA score in the investigated CORTICUS cohort.
Discussion
Starting with a larger panel of predictors from septic shock patients treated with HC or placebo in CORTICUS, we identified the ratio of serum IFNγ and IL10 as a promising biomarker for HC treatment decision. The decision rule was based on data derived from 83 patients. We validated our results by applying the marker and threshold to three other, unseen datasets to validate the potential of the theranostic marker. As in particular the survival rate of the HSSG cohort was very different to CORTICUS, this threshold needed to be adjusted. This was performed by a calibration curve calculated from the CORTICUS dataset mimicking higher death rates in CORTICUS. This led to a positive correlation between the optimal threshold and the mimicked death rate (details, see Supplementary Text S2), i.e. the higher the threshold, the more patients are in a worse condition at baseline (higher incidence of death), and particular these patients were observed to benefit from HC.
Albeit the ratio was identified by machine learning and supported by subsequent in vitro
experiments, there is published evidence for its plausibility as a biomarker for life-threatening infections. IFNγ and IL10 have been suggested as biomarkers for parasitic (20) and other infections, such as tuberculosis (21) . McIlleron et al. reported the time course of IFNγ indicating response to treatment in pulmonary tuberculosis (22) . However, for diagnosis of pulmonary tuberculosis, IFNγ alone has limitations with relation to sensitivity (23) . In turn, high IL10 was observed with mycobacterial persistence (24) suggesting that in particular the ratio of these cytokines might reflect the immunological burden of infection. In line, it has been shown that the ratio of IFNγ and IL10 correlates with the disease severity of tuberculosis and may differentiate pulmonary from extrapulmonary forms (25) . To elucidate the functional implications of low and high IFNγ/IL10, we performed blood culture assays.
Indeed, we observed the ratio to be associated with the pathogen load in ex vivo blood culture experiments. This was supported by data from Matera et al. (19) when regarding critically ill patients with bacteremia (higher bacterial load) and without bacteremia (no or non-detectable bacterial load).
Synoptically, IFNγ/IL10 is associated with pathogen load and thus, severity of sepsis.
Metabolically, high serum lactate indicates severity of cellular disturbances (15) and is associated with poor outcome (26) . Consistent with this, patients with low IFNγ/IL10 showed high serum lactate. Furthermore, stratifying patients in compliance with the proposed decision rule, we observed a considerable decrease over time in serum lactate specifically in the group of patients, which were treated in compliance with the theranostic marker.
IFNγ has been consistently documented to activate cells of adaptive immunity (27) and IL10 as a suppressor of innate immune responses and inflammation (28, 29) . According to this, high IFNγ/IL10 reflects increased activated adaptive and innate immunity. In line, we observed ex vivo that blood challenged with bacterial fragments or LPS, displayed low IFNγ/IL10 at high loads, and vice versa. Transferring these observations to septic shock patients with low IFNγ/IL10, we speculate that HC treatment yielded a better outcome in HCresponders because HC may allow the highly loaded immune system more pace for recovery. This is evidenced, by the reduction of serum lactate and norepinephrine requirements as measures of recovery particularly in the subgroup of very sick patients.
The concern about side effects of corticosteroids such as infections in patients with less severe septic shock stipulated more restrictive recommendations by the Surviving Sepsis Campaign. HC application is currently recommended for patients not responding to adequate fluid resuscitation and vasopressor therapy (30, 31) . It seems intuitively promising to include an immune biomarker, such as IFNγ/IL10 reflecting the status of the patients' immune system. Consistent with this concept, Bentzer et al. studied patients from the VASST trial investigating corticosteroid treated versus non-treated (only vasopressin or catecholamine vasopressors). They identified a signature of three cytokines (IL3, IL6, CCL4) suggesting response to corticosteroid treatment (32) . However, these results are based on a study, which was not randomized, blinded or protocolized according to corticosteroid treatment.
Further, Bentzer et al. did not distinguish between vasopressin and catecholamine treatment, and they didn't elaborate explaining how these three cytokines interact with corticosteroid treatment.
Applying our decision rule successfully across a broad range of studies suggests the marker to be generic and rather independent from specific assays, probably reflecting the on-off kinetics of the quotient.
Limitations and strengths
The relatively small sample sizes along with the high dimensional data sets obtained imply that our results must be interpreted with caution and requires prospective validation. A further limitation of our study was that the use of corticosteroids was not randomized in the HSSG and the SISPCT study. Strengths of our study were that we used well-phenotyped cohorts of patients with septic shock, that our marker showed very similar results across all studies, and that we not only showed the potential clinical relevance but also give a reasonable functional reasoning why this marker may support HC application by investigating ex vivo blood culture experiments.
Conclusions
We identified the ratio of serum cytokines IFNγ and IL10 as a theranostic marker for hydrocortisone treatment in septic shock. An accompanying study into the mechanism suggests that this ratio enables the host to sense the pathogen load in an "on-off" fashion. 
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